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http://dx.doi.org/10Graft-versus-host disease (GVHD), mediated by donor-derived alloreactive T cells, is a major
cause of nonrelapse mortality in allogeneic hematopoietic stem cell transplantation. Its ther-
apy is not well-defined. We established allele-specific anti-human leukocyte antigen (HLA)
monoclonal antibodies (ASHmAbs) that specifically target HLA molecules, with steady death
of target-expressing cells. One such ASHmAb, against HLA-A*02:01 (A2-kASHmAb), was
examined in a xenogeneic GVHD mouse model. To induce fatal GVHD, non-irradiated
NOD/Shi-scid/IL-2Rgnull mice were injected with healthy donor human peripheral blood
mononuclear cells, some expressing HLA-A*02:01, some not. Administration of A2-
kASHmAb promoted the survival of mice injected with HLA-A*02:01-expressing peripheral
blood mononuclear cells (p ! 0.0001) and, in humanized NOD/Shi-scid/IL-2Rgnull mice,
immediately cleared HLA-A*02:01-expressing human blood cells from mouse peripheral
blood. Human peripheral blood mononuclear cells were again detectable in mouse blood 2
to 4 weeks after A2-kASHmAb administration, suggesting that kASHmAb may be safely
administered to GVHD patients without permanently ablating the graft. This approach,
different from those in existing GVHD pharmacotherapy, may open a new door for treatment
of GVHD in HLA-mismatched allogeneic hematopoietic stem cell transplantation. Copy-
right  2015 ISEH - International Society for Experimental Hematology. Published by Elsev-
ier Inc. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/3.0/).Allogeneic hematopoietic stem cell transplantation (allo-
HSCT) can cure hematologic disorders like leukemia [1].
Cord blood or haplo-identical-donor HSCT holds promise
for patients without a human leukocyte antigen (HLA)-
matched donor. However, HLA-mismatched allo-HSCT
may be complicated by alloreactive T cell-mediated graft-
versus-host disease (GVHD), a major cause of mortality
(after recurrent original disease) in allo-HSCT [2].
Although moderate GVHD induces a graft-versus-tumor: Satoshi Yamazaki, 4-6-1 Shirokanedai, Minato-ku,
n; E-mail: y-sato4@ims.u-tokyo.ac.jp
related to this article can be found online at http://
exphem.2014.10.008.
 2015 ISEH - International Society for Experimental Hem
se (http://creativecommons.org/licenses/by-nc-nd/3.0/).
.1016/j.exphem.2014.10.008effect and reduces disease relapse [3–6], severe GVHD
confers a poor prognosis, as it is difficult to control. Agents
used to treat GVHD include steroids [7], calcineurin inhib-
itors [8], and anti-thymocyte globulin (ATG) [9,10]. While
these work well, they have many side effects (opportunistic
infection, anaphylaxis-like reactions, etc.), which clinicians
must carefully monitor.
Antithymocyte globulin endures as an antibody-based
drug for GVHD treatment; however, its polyclonality and
nonspecified target molecule cause it to react not only with
T cells but also with other cells [9,10]. Current alternative
therapies include monoclonal antibodies such as anti-CD3
[11] and anti-CD52 [12,13]. These antibodies have target
molecules far more specific than those of ATG, but they
cannot discriminate host cells from donor cells, resulting
in opportunistic infection and other serious adverse effects.atology. Published by Elsevier Inc. This is an open access article under the
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that they affect every cell without distinction between donor
and recipient cells. Damage to cells of both the donor and the
recipient causes side effects that impair long-term prognosis
such as organ failure and immune compromise. Therefore,
we suggest a novel therapeutic approach to GVHD using
an antibody that specifically recognizes a donor HLA mole-
cule and damages only donor-derived cells.
Flow cytometry using anti-HLA antibodies is useful for
determination of chimerism and minimal residual disease
after HLA-mismatched HSCT [14]. Allele-specific anti-
HLA monoclonal antibodies (ASHmAbs) are notoriously
more difficult to generate than are non-allele-specific anti-
HLA antibodies. However, we established a rapid and effi-
cient strategy to generate ASHmAb using HLA-transgenic
mice [15]. Allele-specific antibodies thus generated can
damage target cells quickly and selectively; we assessed
whether or not ASHmAb can treat GVHD in a mouse
model. This report describes the success of a novel thera-
peutic approach to GVHD with ASHmAb that recognizes
donor and recipient cells allele-specifically, damaging
only donor-derived cells.Methods
Mice
NOD/Shi-Scid Jic (NOD/SCID) mice were purchased from San-
kyo Laboratory (Ibaraki, Japan). NOD/Shi-scid/IL-2Rgnull
(NOG) mice were purchased from the Central Institute for Exper-
imental Animals (Kanagawa, Japan). HLA-B51 (B*5101) trans-
genic mice were all bred and maintained in the Animal
Research Facility of the Institute of Medical Science, University
of Tokyo. Animal care in our laboratory was in accordance with
the guidance of the University of Tokyo for animal and recombi-
nant DNA experiments.
Human samples
Human peripheral blood mononuclear cells (PBMCs) were
collected from healthy donors at the University of Tokyo, and
human cord blood was obtained from the Japanese Red Cross
Kanto-Koshinetsu Cord Blood Bank, according to protocols
approved by the institutional review board of the Institute of Med-
ical Science, University of Tokyo. Mononuclear cells were iso-
lated by centrifugation of human PBMCs on Lymphosepar I
(Immuno-Biological Laboratories, Gunma, Japan). The isolated
cells were washed once with ice-cold phosphate-buffered saline,
suspended in a small volume of phosphate-buffered saline contain-
ing 5% mouse serum (Dako, Glostrup, Denmark) to block nonspe-
cific fluorescence-labeled antibody binding to immunoglobulin Fc
receptors, and kept on ice until staining.
Flow cytometric analysis
Studies of human-derived cells in humanized mice or GVHD
model mice were performed using fluorescein isothiocyanate-
conjugated anti-HLA-A9 (OneLambda, Canoga Park, CA, USA)
and anti-human lineage CD3, 14, 16, 19, 20, and 56 (BioLegend,
San Diego, CA, USA); phycoerythrin (PE)-conjugated anti-HLAA2 (BD Biosciences, San Jose, CA) and anti-CD56 (BioLegend);
PE/cyanine (Cy) 5-conjugated anti-CD235ab (BD Biosciences);
peridinin chlorophyll/Cy5.5-conjugated anti-CD8 (BioLegend);
PE/Cy7-conjugated anti-CD3, anti-CD33 (BD Biosciences) and
anti-CD38 (BD Biosciences); allophycocyanin (APC)-conjugated
anti-CD3 (BioLegend) and anti-CD34 (BD Biosciences); APC/
Cy7-conjugated anti-CD19 (BioLegend); Pacific blue-conjugated
anti-CD4 and anti-CD45 (BioLegend); and Alexa Fluor 405- or
647-conjugated anti-CD45 (BioLegend). Propidium iodide (PI,
1 mg/mL; Sigma–Aldrich, St. Louis, MO, USA) was added to sam-
ples to stain dead cells just before flow cytometric analysis.
Becton-Dickinson AriaII & CantoII fluorescence-activated cell
sorters were used for all multicolor FACS analysis and sorting.
Flow cytometry standard data were analyzed using FlowJo soft-
ware (Treestar, Ashland, OR, USA).
Establishment of ASHmAb
We followed the method of Yamazaki et al. to generate ASHmAb
[15] using PE-conjugated anti-HLA A2 tetramer loaded with
NLVPMVATV peptide (HLA-A*02:01-restricted human
cytomegalovirus-specific epitope pp65) and PE-conjugated anti-
HLA A24 tetramer loaded with QYDPVAALF peptide (HLA-
A*24:02-restricted human cytomegalovirus-specific epitope
pp65), which were purchased from Medical and Biological Labo-
ratories (Nagoya, Japan). FlowPRA screening (OneLambda) was
performed according to the manufacturer’s instructions. The
isotypes of kASHmAb selected were IgM (HLA-A9) and IgG2b
(HLA-A2) by Rodent Monoclonal Isotyping Strips (AbD Serotec,
Kidlington, UK). We used an Alexa Fluor 647 monoclonal anti-
body labeling kit (Life Technologies, Carlsbad, CA, USA) to label
kASHmAbs.
Examinations of peripheral blood
Analyses of mouse retro-orbital venous plexus blood samples
were performed using a Celltac a (Nihon Kohden, Tokyo, Japan)
to obtain complete blood counts and a Dri-Chem 3000 (Fujifilm,
Tokyo, Japan) to measure serum total bilirubin and lactate dehy-
drogenase, alanine aminotransferase, and aspartate aminotrans-
ferase activities.
Xenogeneic model of GVHD
Non-irradiated female NOG mice 9 to 10 weeks old were injected
intravenously with 1.0  107 human PBMCs (day 0) and were
treated with ASHmAb (3 mg/g/day) on days 3 and 4 (total dose:
120 mg/mouse).
Purification of human CD34-positive cells and xenogeneic
transplantation
Human CD34-positive cells from cord blood mononuclear cells
were enriched using anti-human CD34 Micro-beads (Miltenyi
Biotec, Bergisch Gladbach, Germany). For transplantation, female
NOD/SCID mice or NOG mice 6 to 8 weeks old were irradiated
(1.5 to 2.0 Gy) before transplantation, and 1.0 to 2.0  105 live
CD34-positive cells were injected by tail vein. Live cells were
identified by microscopy as those able to exclude trypan blue.
Systemic assessment of GVHD
To evaluate GVHD symptoms, we chose objective measurements
(loss of weight, change of body temperature, and changes in
biomarker values). Body weights and body temperatures of all
mice were determined twice weekly. The liver, gut, kidneys, and
Figure 1. Assessment of allele specificity of kASHmAbs. (A) To establish ASHmAb-producing clones, on day 28 hybridomas (Supplementary Fig. E1, on-
line only, available at www.exphem.org) selected as producing anti-HLA antibody at initial screening were secondarily screened with FlowPRA, using flow
cytometry (YNA2.8.2 and YNA2.12.2). Hybridoma culture supernatants were incubated with HLA-coated beads. After incubation, the beads were washed
and stained with secondary antibodies. Bead fluorescence intensities were measured using a flow cytometer, and specificities of anti-HLA monoclonal an-
tibodies were determined. Representative flow cytometry data are shown for a combination of FlowPRA beads coated with HLA-A*01:01, A*02:01,
A*03:01, B*49:01, A*25:01, A*29:02, A*30:01, and control antigen or A*26:01. (B) Flow cytometric analysis of A2-ASHmAb with healthy donor PBMCs.
PBMCs No. 2 express HLA-A*02:01; PBMCs No. 1 do not. We stained three types of PBMCs (PBMCs No. 1 only, PBMCs No. 2 only, and PBMCs No.
1 þ No. 2) with Alexa Fluor 647-conjugated ASHmAb to assess this antibody’s specificity. Cells from PBMCs No. 1 þ No. 2 sorted as HLA-A2(þ) were
subjected to sequencing-based HLA typing. (C) Chimerism analysis of clinical samples using ASHmAb. In a 46-year-old man who underwent cord blood
transplantation more than 12 years earlier for acute myeloid leukemia, we analyzed chimerism of whole PBMCs, B cells, T cells, natural killer cells, and
monocytes using anti-HLA A2 (recipient), anti-HLA A24 (recipient and donor), and anti-human CD3, CD4, CD8, CD19, and CD56. Doublets and dead cells
were excluded from flow cytometry data. ASHmAbs 5 allele-specific anti-human leukocyte antigen monoclonal antibodies; HLA 5 human leukocyte an-
tigen; kASHmAbs 5 ASHmAbs; PBMCs 5 peripheral blood mononuclear cells.
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microscopy of immunostained sections. Animal cages were main-
tained at room air temperature of 22C to 23C with a humidity of
55%.
Immunostaining of organ sections
Liver, lungs, guts, and kidneys from mice transplanted with hu-
man PBMCs were fixed with 10% buffered formalin and
embedded in paraffin. Sections 5 mm thick were placed on glass
slides (Matsunami Glass, Osaka, Japan), deparaffinized, incu-
bated with anti-human CD3 and CD45 monoclonal antibodies
(Dako) overnight at 4C, and serially incubated with
peroxidase-labeled polymer conjugated goat anti-mouse antibody
(Nichirei, Tokyo, Japan) for 30 min at room temperature. These
sections then were incubated with 0.02% 3,3-diaminobenzidine
(Dojindo, Kumamoto, Japan) substrate solution containing
0.006% H2O2 and counterstained with hematoxylin for visualiza-
tion of nuclei. TdT-mediated dUTP nick end labeling (TUNEL)
staining (Medical and Biological Laboratories) was performed
according to the manufacturer’s instructions to permit evaluation
of apoptosis.
Statistics
Mouse survival data are presented as Kaplan–Meier survival
curves. Differences between groups were analyzed by log-rank
testing with GraphPad Prism (GraphPad Software, San Diego,
CA, USA). Differences between group means were tested using
Student’s t test, also with GraphPad Prism; values for which
p ! 0.05 were considered significant.Results
Generation of ASHmAbs and their specificities
Using our established method [15], we developed a panel of
ASHmAbs that recognize HLA alleles specifically. First,
we immunized HLA class I transgenic mice with tetramers
specific for HLA-A or HLA-B alleles [16]. After alloim-
munity was confirmed by assay of sera from immunized
mice, the mice were sacrificed and lymph node-derived
cells and splenic cells were fused with SP2/0 myeloma cells
to yield hybridoma cells (Supplementary Figure 1E, online
only, available at www.exphem.org). We screened superna-
tants of hybridomas in single-clone culture by enzyme-
linked immunosorbent assay to detect reactivity against
the HLA tetramer (data not shown). Selected clones were
expanded for panel-reactive antibody (PRA) screening, per-
formed using FlowPRA (Fig. 1A). We chose several mono-
clonal antibodies for further work, one binding specifically
to HLA-A*02:01 (YNA2.8.2) and one binding to both
HLA-A*02:01 and HLA-A*03:01 (YNA2.12.2). We also
established the antibodies that bind to HLA-A*23:01,
HLA-A*24:02, and HLA-A*32:01 (Clone YNA24.3.2 and
YNA24.19.2). Focusing on YNA2.8.2, we purified it and
subjected it to biotinylation or to conjugation with the fluo-
rescent chromophore AF647. Using this biotinylated ASH-
mAb or the ASHmAb’s fluorescent conjugate, we analyzed
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two different HLA-positive healthy donor PBMC sets. We
mixed PBMCs from two donors, one HLA-A2-positive
and the other HLA-A2-negative, and stained the pool
with biotinylated ASHmAb. Flow cytometry results re-
vealed that we could distinctly separate the two types of
cells (Fig. 1B). With sequencing-based typing (Special
Reference Laboratories, Tokyo, Japan), we confirmed that
cells sorted as HLA-A*02:01 positive were absolutely, by
genetic criteria, HLA-A*02:01 expressing (data not
shown). To confirm this antibody’s specificity in vivo
further, we analyzed PBMCs of a patient who underwent
allo-HSCT to examine whether the antibody enabled sepa-
ration of donor (HLA-A2-negative/A24-positive) cells from
recipient (HLA-A2/A24-positive) cells (Fig. 1C). The pa-
tient was a 46-year-old man who 12 years earlier had under-
gone cord blood transplantation for acute myeloid leukemia
and who suffered from chronic GVHD. Using YNA2.8.2,
we could successfully separate the patient’s PBMCs into
donor- and recipient-derived cells. Chimerism analysis un-
expectedly revealed that T cells, B cells, natural killer (NK)
cells, and monocytes of native origin persisted in this pa-
tient after HSCT. These results confirm the reported utility
of ASHmAbs as a diagnostic tool [14].
Allele-specific cytotoxicity of ASHmAb
To evaluate the killing ability of ASHmAb, we first
analyzed in vitro cytotoxicity (Fig. 2A). HLA-A2-
negative or -positive cells (1.0  106 cells/well) were
cultured with ASHmAb hybridoma supernatant, Dulbecco’s
modified Eagle medium (Sigma–Aldrich), and 10% fetal
bovine serum, with or without 30% baby rabbit comple-
ment, and were incubated for 24 hours (37C, 5%CO2).
Percentages of dead cells were determined by PI staining
of cells using a flow cytometer. On average, 61.9% of
HLA-A2-positive cells were PI positive, and on average,
only 14.2% of HLA-A2-negative cells were PI positive.
These results indicate that ASHmAb can bind with
HLA-A2-positive cells in vitro, a phenomenon resulting
in cell death, presumably via complement-dependent cyto-
toxicity. We designated this ASHmAb that kills only
HLA-A*02:01-positive cells as HLA-A2 killing ASHmAb
(A2-kASHmAb). A2-kASHmAb was capable of killing
target cells quickly: when we examined cell death after
3 hours of incubation, we found 30% to 40% mortality
manifest as aggregation and failure of trypan blue exclusion
(data not shown).
To analyze the cytotoxicity of A2-kASHmAb in vivo,
we transplanted 1.0  105 cells/mouse cord blood-derived
HLA-A2-negative or -positive mononuclear cells into
CB17-Prkdcscid/J (NOD/SCID) mice previously subjected
to 2.0 Gy of irradiation and made human–mouse bone
marrow chimeric mice (Fig. 2B). Before A2-kASHmAb in-
jection (0.5 mg/mouse, intravenously), chimerism of cord
blood-derived HLA-A2-positive cells was 12.0%; 1 dayafter injection, chimerism fell to 0.3%. Conversely, chime-
rism of cord blood-derived HLA-A2-negative cells before
A2-kASHmAb injection was 2.3% and 1 day after injec-
tion, chimerism increased to 5.9% (Fig. 2C), an effect
significantly different on statistical analysis (Fig. 2D, E).
These experiments indicate that kASHmAb can damage
cells allele-specifically in vitro and in vivo. We also found
that kASHmAb administered intraperitoneally could dam-
age target cells as efficiently as kASHmAb administered
intravenously (Supplementary Figure E2A–C, online only,
available at www.exphem.org).
Xenogeneic model of GVHD treatment with kASHmAb
We focused on kASHmAb’s cytotoxicity and its ability to
discriminate between donor and recipient cells. ATG, a
representative clinical GVHD molecular-targeted agent, is
used both as a treatment for and as a prophylactic against
GVHD. However, ATG reacts against cells without distin-
guishing between donor and recipient cells and causes
many side effects, such as allergic reaction and increased
susceptibility to infection, as a result of repression of T
cells. Moreover, the exact molecular target of ATG is un-
known, because ATG is polyclonal. As kASHmAb induces
donor-specific cell death in GVHD treatment and is
directed against a clear molecular target, we thought that
kASHmAb might be useful as a molecule-targeted drug
in GVHD treatment as an alternative to ATG.
Ito et al. reported a novel xeno-GVHD animal model us-
ing NOG mice in which, thanks to intravenous transfer of
human PBMCs, GVHD symptoms were of early onset
[17]. We employed this model to analyze the therapeutic ef-
fect of kASHmAb in GVHD. We transplanted 1.0  107
cells/mouse HLA-A2-negative or -positive PBMCs into
NOG mice without irradiation (day 0). To judge whether
GVHD had developed or not, blood tests, determinations
of body temperature and weight, and assays of skin damage
were used in previous studies [18–20]. In this study, to
ensure as objective a determination of the onset of
GVHD as possible, we decided to define GVHD onset
based on minor changes in biomarker values, body
temperature, and body weight, as in clinical settings
(Fig. 3C, Supplementary Figure E3, online only, available
at www.exphem.org). Determinations of complete blood
counts (CBC) and biomarkers in peripheral blood estab-
lished that the onset of GVHDdas indicated by significant
changes in complete blood count valuesdwas 3 days after
PBMC injection. We thus decided to start administration of
A2-kASHmAb from this point with A2-kASHmAb injec-
tion (days 3 and 4; 60 mg/day  2 days) coupled with anal-
ysis of PBMCs by flow cytometry (Fig. 3A); complete
blood count and biomarker determinations; records of
body weight, body temperature, and calculated survival
rate; and histopathologic analysis. First, using flow cytom-
etry, we analyzed the frequency of human-derived cells
in peripheral blood of GVHD model mice before and after
Figure 2. Allele-specific cytotoxicity of ASHmAbs. (A) Statistical analysis of in vitro killing assay using A2-ASHmAb with and without baby rabbit com-
plement (right and left, respectively). HLA-A2() cells (red bar) and HLA-A2(þ) cells (blue bar) from healthy donors were each cultured with isotype
control or A2-ASHmAb hybridoma supernatant. Percentages of dead cells were determined by propidium iodide staining and flow cytometry. Doublets
and dead cells were excluded from flow cytometry data. NC 5 negative control; NS 5 not significant. Data shown as mean 6 SD (n 5 4, p ! 0.05 by
Student’s t test). (B) Schedule of in vivo assay of killing ASHmAbs. Cord blood-derived CD34(þ)/HLA-A2() or CD34(þ)/HLA-A2(þ) cells were trans-
planted into NOD/SCID mice with 2 Gy of irradiation to create respectively HLA-A2() and HLA-A2(þ) human–mouse bone marrow chimeric mice. One
month after transplantation, peripheral blood was analyzed by flow cytometry just before kASHmAb injection and on days 1 and 7 thereafter. (C) Repre-
sentative flow cytometric analyses. Top: HLA-A2()/CD45(þ) cells (%) among HLA-A2() mouse peripheral blood mononuclear cells in marked gate.
Bottom: HLA-A2(þ)/CD45(þ) cells (%) among HLA-A2(þ) mouse PBMCs in marked gate. Doublets and dead cells were excluded from flow cytometry
data. (D, E) Statistical analysis of (C). Red bars and blue bars respectively represent HLA-A2() and HLA-A2(þ) cells. Data shown as mean 6 SD (n 5 3
and 5, respectively; p ! 0.05 by Student’s t test). HLA 5 human leukocyte antigen; kASHmAbs 5 killing allele-specific anti-human leukocyte antigen
monoclonal antibodies; NS 5 not significant; PBMCs 5 peripheral blood mononuclear cells.
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HLA-A2-positive group was 5.4% before A2-kASHmAb
injection; on day 8 after PBMC injection, it was 0%.
Chimerism of the HLA-A2-negative group was 8.8%
immediately before A2-kASHmAb injection; on day 8 after
PBMC injection, it was 27.8%. The survival rate of the
HLA-A2-positive group was 100%, with a mean survival
of more than 6 months; however, all members of the
HLA-A2-negative group died within 2 months (Fig. 3D).
To confirm that GVHD had caused death, we histopatholog-ically examined liver, lungs, intestine, and kidneys of these
mice. Immunostaining revealed intensive tissue infiltration
by CD3-positive/CD45-positive cells, especially in lungs
and intestine (Fig. 3E, Supplementary Figure E4, online
only, available at www.exphem.org), and TdT-mediated
dUTP nick end labeling studies revealed apoptosis
(Supplementary Figure E5, online only, available at www.
exphem.org). These results verified experimentally that
kASHmAb could be a novel drug to damage target cells
in GVHD safely, quickly, and selectively.
Figure 3. GVHD kASHmAb treatment model. (A) Schedule, GVHD kASHmAb treatment model. Day 1: Blood examination. Day 0: HLA-A2() or
HLA-A2(þ) PBMCs transplanted into non-irradiated NOG mice. Day 3: Blood examination immediately before first kASHmAb dose; first kASHmAb
dose. Day 4: Second kASHmAb dose. Days 2, 8, and 28: Flow cytometric analyses. Day 90: Survival assessment. (B) Representative flow cytometric an-
alyses. Human-derived cells (%) among GVHD model mouse PBMCs, days 3, 8, and 28. Top: HLA-A2()/CD45(þ) cells, HLA-A2() GVHD mouse.
Bottom: HLA-A2(þ)/CD45(þ) cells in HLA-A2(þ) GVHD mouse. Forward-scatter, side-scatter, and propidium iodide gatings excluded residual erythro-
cytes, debris, doublets, and dead cells. (C) Body weight of GVHD model mice before and after kASHmAb treatment. Red line 5 HLA-A2() PBMC-
transplanted mice 5 GVHD(þ); blue line: HLA-A2(þ) PBMC-transplanted mice 5 GVHD()]. Weight was determined twice weekly between 1500
and 1900 hours at room temperature (22C) and ambient humidity (55%). Percentage change from initial weight is illustrated. (D) Survival of GVHD model
mice (kASHmAb-treated). Red and blue lines respectively represent HLA-A2() GVHD mice and HLA-A2(þ) GVHD mice. Data shown as Kaplan–Meier
estimates (n 5 4 and 5, respectively; p ! 0.05).
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Figure 3. (continued) (E) Lung and intestine, day 21, GVHD model mice (NOG mice intravenously transplanted with human PBMCs (HLA-A2() or
HLA-A2(þ)); anti-human CD3 and CD45 developed with 3,30-diaminobenzidine, hematoxylin nuclear counterstaining.  200. Bar 5 400 mm.
A 5 alveoli; Br 5 bronchiole; GVHD 5 graft-versus-host disease; HE 5 hematoxylin and eosin; HLA 5 human leukocyte antigen;
kASHmAbs 5 allele-specific anti-HLA monoclonal antibodies against HLA-A*02:01; LP 5 lamina propria; Lu 5 lumen; M 5 muscularis; NOG 5
NOD/Shi-scid/IL-2Rgnull; PBMCs 5 peripheral blood mononuclear cells; S 5 submucosa.
85Y. Nakauchi et al./ Experimental Hematology 2015;43:79–88kASHmAb administration did not cause graft failure
We confirmed that A2-kASHmAb specifically damages
cells that express HLA-A2 in human–mouse bone marrow
chimera mice (Fig. 2C, D). A potential risk of anti-
GVHD therapy with kASHmAb is damage to donor he-
matopoietic stem cells (HSCs) that necessitates another
transplantation. Unexpectedly, we discovered that in many
mice (14 of 16) in the HLA-A2-positive group chimerism
rebounded to high levels 1 to 2 months after A2-
kASHmAb injection. The dose of kASHmAb used to treat
GVHD was, at greatest, equivalent to that of the polyclonal
ATG preparation usually given for acute GVHD in actual
clinical settings (3 mg/kg/day  5 days). The clinical risk
might be substantial if kASHmAbs were administered to
GVHD patients, because if donor-derived HSCs are abla-
ted, patients may have to undergo HSCT again. The obser-
vation that chimerism returns quickly after A2-kASHmAb
administration let us hypothesize that HSCs resist
antibody-mediated killing and that adjusting the dose of
kASHmAb may circumvent damage to HSCs while yet
treating GVHD.We used humanized mice, generated by transplanting
2.0  105 cells/mouse cord blood-derived HLA-A2-
positive/CD34-positive cells into NOG mice after 1.5 Gy
irradiation, to track numbers of cord blood-derived HLA-
A2-positive/CD45-positive human cells among mouse
PBMCs and bone marrow cells after high-dose A2-
kASHmAb (60 mg/day  2 days) administration
(Fig. 4A). PBMC human cell chimerism in humanized
mice immediately before A2-kASHmAb injection was
72.2%; 2 days after A2-kASHmAb injection, it was
12.9%. Although most CD34-positive cord blood-derived
cells disappeared after A2-kASHmAb injection, human
cell high chimerism (70.7%) returned in the same mice
within 1 month (Fig. 4B, C). We determined numbers of
human cells in mouse PBMCs and bone marrow cells
before and after A2-kASHmAb injection. Although many
human PBMCs disappeared, the proportion of human-
derived cells in bone marrow continued to be substantial
(Fig. 4D). HLA resides on the surface of all nucleated cells,
including HSCs [21,22]; these results unexpectedly indi-
cated that the killing ability of kASHmAb is selective,
Fig. 4. Humanized mice: kASHmAb treatment without graft failure. (A) Schedule. (B) Representative flow cytometric analyses. Cord blood-derived human
cells (%) among PBMCs of irradiated NOD/Shi-scid/IL-2Rgnull (NOG) mice given HLA-A2(þ)/CD34(þ) cord blood cells; ‘‘humanized mice,’’ day 1 (day
before intraperitoneal kASHmAb injection) and days 2, 7, 28, 56, and 84. Abscissa: Human CD45; ordinate: HLA-A2. Forward-scatter, side-scatter, and
propidium iodide gatings excluded residual erythrocytes, debris, doublets, and dead cells. (C) Bars: HLA-A2(þ)/CD45(þ) cells (%) among humanized
mouse PBMCs. The data are normalized against the baseline percentage of human cells. Data shown as mean 6 SD (n 5 5). (D) Representative flow cyto-
metric analyses of cord blood-derived human cells (%) among bone marrow cells, say 84. Mouse bone marrow cells were stained with anti-human CD34 and
anti-human CD38 antibodies. Forward-scatter, side-scatter, and propidium iodide gatings excluded residual erythrocytes, debris, doublets, and dead cells.
HLA 5 human leukocyte antigen; kASHmAbs 5 killing allele-specific anti-HLA monoclonal antibodies against HLA-A*02:01; NOG 5 NOD/Shi-scid/
IL-2Rgnull; PBMCs 5 peripheral blood mononuclear cells.
86 Y. Nakauchi et al./ Experimental Hematology 2015;43:79–88damaging cells in peripheral blood more efficiently than
those in bone marrow. These findings indicated that at the
correct dose, kASHmAb likely could be administered to
GVHD patients safely, without causing graft failure and
necessitating repeat HSCT.Discussion
Emergence of antibodies to HLA antigens is often associ-
ated with disorders such as graft failure and resistance to
transfusion [23–27]. This study is the first to find thatanti-HLA antibodies also can be used therapeutically. Con-
fronted with growing numbers of HLA-mismatched cord
blood or haplo-identical HSCT, we thought about gener-
ating kASHmAbs that can recognize donor HLA molecules
in an allele-specific manner and damage them while sparing
host cells. Because they act specifically against donor cells,
these kASHmAbs, in principle, should constitute novel
anti-GVHD drugs with minimum side effects. Indeed, un-
like ATG and anti-CD3 or anti-CD52 antibodies, ASH-
mAbs destroyed donor cells specifically and quickly and
thus treated acute GVHD efficiently, as shown in our
87Y. Nakauchi et al./ Experimental Hematology 2015;43:79–88GVHD-model mice. Many models have been developed to
manipulate, and to clarify, human T-cell-mediated acute
GVHD in vivo [28]. The model that we used is optimal
for evaluation of the killing ability of ASHmAbs, because
it is very simple; it is reproducible; and most of all, the im-
mune response is typically more robust to xenografts than
to allografts.
We thought that graft failure requiring second transplan-
tation was a potential adverse effect of kASHmAb admin-
istration, because the antibody might target for
elimination all donor-type HLA-expressing cells, in partic-
ular, HSCs (which are known to express high levels of class
I major histocompatibility complex) [21,22]. Unexpectedly,
human PBMCs reappeared in mouse peripheral blood 2 to
3 weeks after kASHmAb administration at very high doses.
This suggests that the cytotoxic effect of kASHmAb may
preferentially injure mature PBMCs, sparing hematopoietic
stem progenitor cells. The mechanism of this preference is
not clear at present. It could be due to the fact that most
HSCs in the bone marrow niche are in a quiescent state
and resistant to cell damage such as apoptosis [29,30].
Although the concern persists that patients given kASH-
mAb are at risk of graft failure, optimization of kASHmAb
dosages may solve this issue.
So far, we have generated kASHmAbs against HLA-A2
and HLA-A24 (Supplementary Figure E6, online only, avail-
able at www.exphem.org). These two kASHmAbs can cover
approximately 23.1% of HLA-mismatched transplants (data
from our institute). More kASHmAbs are needed to cover
other HLA-mismatched transplants. For example, if we
establish 12 more kASHmAbs (HLA-A*02:03, HLA-
A*02:06, HLA-A*02:07, HLA-A*24:02, HLA-A*24:20,
HLA-A*11:01, HLA-A*26:02, HLA-A*31:01, HLA-
A*33:03, HLA-B*35:01, HLA-B*40:02, and HLA-
B*51:01), at least 72.3% of GVHD cases (n 5 199) in our
institute can be treated. As an alternative to class I kASH-
mAbs, we have succeeded in generating several HLA class
II ASHmAbs. These mAbs can potentially target activated
T cells and antigen presenting cells that play a central role
in eliciting GVHD. Administration of them alone or in com-
bination with class I kASHmAbs may further enhance the
anti-GVHD effect but minimize side effects.
Furthermore, if the diagnosis of GVHD can be made
earlier using recently discovered biomarkers of early
GVHD [31], for example, we may be able to treat GVHD
safely with low doses of kASHmAb. Should target cells
evade kASHmAbs by internalizing HLA molecules [32],
kASHmAbs can be labeled with cell-damaging agents
such as anti-cancer drugs and radio-isotopes [33,34],
thereby inducing cell death. If HLA expression is downre-
gulated [35,36], cell surface expression of HLA can be
induced with drugs such as interferon-g [37]. An additional
concern in treatment of GVHD with kASHmAbs is their in-
fluence on the graft-versus-tumor (GVT) effect. Although
little is known about how GVT and GVHD effects differ,clearly in most cases there will be no GVT effect without
GVHD. To observe the GVT effect even after treatment
of GVHD with either class I or class II kASHmAbs will
pose intriguing questions.
In conclusion, kASHmAb is an antibody that accurately
discriminates between donor and recipient cells and in-
duces target cell death. As use of HLA-mismatched cord
blood transplantation and haplo-identical HSCT increases,
so may the incidence of GVHD. ASHmAbs may provide
an effective treatment for GVHD, favorably influencing
the outcome of allo-HSCT. We believe that kASHmAbs,
ready-made agents created through well-designed anti-
body-processing technologies, have great potential in the
clinical treatment of GVHD.Acknowledgments
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Supplementary Figure E1. Schedule for ASHmAb generation and screening. Day 0: First immunization of HLA-transgenic (Tg) mouse with HLA tetramer.
Day 9: Mouse serum assessed for antibodies. Day 10: Second immunization (boost injection) of HLA-Tg mouse with HLA tetramer. Day 13: Fusion of
spleen- and lymph node-derived B cells with SP2/0 myeloma cells. Fused cells were cultured in medium without aminopterin for 24 hours. Day 14: Sus-
pension of fused cell-daughter cell candidates in methylcellulose-based HAT medium in 10-cm dishes for culture pending selection. Days 20-22: Selection
of hybridoma colonies replating into 96-well plates filled with Dulbecco’s modified Eagle medium. Days 27-28: Screening of supernatants from hybridoma
culture; initially by enzyme-linked immunosorbent assay, secondarily by flow cytometry. ELISA 5 enzyme-linked immunosorbent assay; HAT 5 hypoxan-
thine-aminopterin-thymidine; HLA 5 human leukocyte antigen.
Supplementary Figure E2. Allele-specific cytotoxicity of HLA-A2-killing ASHmAb (kASHmAb) when injected intraperitoneally (IP). (A, B) Schedule
and representative examples of in vivo assay of IP-administered HLA-A2 kASHmAb. Cord blood-derived CD34(þ) / HLA-A2(þ) cells were transplanted
into irradiated NOD/SCID mice to create human-mouse bone marrow chimeric mice. One month after transplantation, flow-cytometric peripheral blood anal-
ysis was performed just before IP kASHmAb injection (0.5 mg, single dose) and on days 1 and 7 thereafter. Flow-cytometric analysis results show percent-
ages of HLA-A2(þ) / human CD45(þ) cells in the marked gate. Doublets and dead cells were excluded. (C) Results of statistical analysis of (B). Blue bars
represent HLA-A2(þ) cells among humanized-mouse peripheral blood mononuclear cells (PBMC). Data shown as mean 6 s.d (n53, p! 0.05 by Student’s
t-test). ASHmAb 5 allele-specific anti-HLA monoclonal antibody; HLA 5 human leukocyte antigen.
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Supplementary Figure E3. Results of hematologic and biomarker studies of GVHD-model mice before and after kASHmAb treatment. (A) Blood was
sampled from the retroorbital venous plexus and examined on days -1 (just before PBMC transplantation) and 3 (just before kASHmAb injection). We deter-
mined complete blood counts (CBC; hematocrit with red blood cell, hemoglobin, and platelet concentrations), serum total bilirubin concentration, LDH,
GOT, and GPT activities in 5 HLA-A2(-) PBMC-transplanted mice and 6 HLA-A2(þ) PBMC-transplanted mice. All mice were 7-8 weeks old. Paired
t-test, *P!0.05; **P!0.01; NS: not significant. (B) Body temperature of GVHD-model mice before and after kASHmAb treatment [Red line;
HLA-A2(-) PBMC-transplanted mice5 GVHD(þ), Blue line; HLA-A2(þ) PBMC-transplanted mice5 GVHD(-)]. Body temperature was determined twice
weekly between 1500h and 1900h at room temperature 22C and ambient humidity 55%. Percentage change from initial weight is shown. HLA 5 human
leukocyte antigen; RBC 5 red blood cells; LDH 5 lactate dehydrogenase; GOT 5 glutamic oxaloacetic transaminase; GPT 5 glutamic pyruvic transam-
inase; GVHD 5 graft-versus-host disease; PBMC 5 peripheral blood mononuclear cell.
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Supplementary Figure E4. Tissues from GVHD-model mice immunostained for human antigens (kidney and liver). Three weeks after transplantation, liver
and kidneys were obtained from NOD/Shi-scid/IL-2Rgnull mice intravenously transplanted with human PBMCs [HLA-A2(-) or HLA-A2(þ)]. Sections of
routinely processed formalin-fixed, paraffin-embedded material were stained with anti-human CD3 and CD45 antibodies with 3,3’-diamino-benzidine (DAB)
substrate as chromogen and hematoxylin as nuclear counterstain. While HLA-A2(þ) GVHD mouse shows no human derived-cells, HLA-A2(-) GVHD
mouse organs show human CD3 or CD45 cells; magnification, original image, x200, liver; x400, kidney). Scale bar 400 mm (kidney: 200 mm). B 5 Bile
duct; C 5 Central vein; G 5 Glomerulus; GVHD 5 graft-versus-host disease; H 5 Hepatic artery; HE 5 hematoxylin and eosin; HLA 5 human leukocyte
antigen; PBMC 5 peripheral blood mononuclear cell ; PV 5 Portal vein; R 5 Renal corpuscle.
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Supplementary Figure E6. Allele-specific cytotoxicity of HLA-A24-killing ASHmAb (in vitro). (A) To establish ASHmAb-producing clones, on day 28
hybridomas (Supplementary Fig. 1) selected as producing anti-HLA antibody at initial screening were secondarily screened with FlowPRA, using flow
cytometry (YNA24.3.2 and YNA24.19.2). Hybridoma-culture supernatants were incubated with HLA-coated beads. After incubation, the beads were washed
and stained with secondary antibodies. Bead fluorescence intensities were measured using a flow cytometer and specificities of anti-HLA monoclonal anti-
bodies were determined. Representative flow cytometry data are shown for a combination of FlowPRA beads coated with HLA-A*68:01, A*11:01, A*34:01,
A*24:02, A*32:01, A*33:01, A*31:01, and control antigen or A*23:01. (B) Statistical analysis of in vitro killing assay using A24 ASHmAb with baby-rabbit
complement. HLA-A24(-) cells (red bar) and HLA-A2(þ) cells (blue bar) from healthy donors were each cultured with isotype control or A24 ASHmAb
hybridoma supernatant. Percentages of dead cells were determined by propidium iodide staining and flow cytometry. Doublets and dead cells were excluded
from flow-cytometry data. NC; Negative control. NS; Not significant. Data shown as mean 6 s.d (n54, p! 0.05 by Student’s t-test). ASHmAb 5 allele-
specific anti-HLA monoclonal antibody; HLA5 human leukocyte antigen; kASHmAb5 killing ASHmAb; NC 5 negative control; NS 5 nonsignificant; PI
5 propidium iodide.
Supplementary Figure E5. Apoptosis in sections of organs of HLA-A2(-) and HLA-A2(þ) GVHD-model mice after TdT-mediated dUTP nick end-labeling
(TUNEL). Using routinely processed formalin-fixed, paraffin-embedded material, we evaluated apoptosis in sections of liver, lungs, intestine, and kidneys of
HLA-A2(-) and HLA-A2(þ) GVHD-model mice, obtained 3 weeks after transplantation, by light microscopy after TdT-mediated dUTP nick end-labeling.
Green dots indicate apoptotic cells. Magnification, original images, x200. Scale bars 400 mm. A 5 Alveoli; B 5 Bile duct; Br 5 Bronchiole; G 5 Glomer-
ulus; GVHD 5 graft-versus-host disease; H 5 Hepatic artery; HLA 5 human leukocyte antigen; LP 5 Lamina propria; M 5Muscularis; PV 5 Portal vein;
S 5 submucosa.
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